Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Joo-Young Byun, Sun-Kyeong Park, Boon Peng Ng, Yi-Shao Liu, Chae-Rin Kim & Chanhyun Park. (2022) A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). Expert Opinion on Pharmacotherapy 23:11, pages 1247-1257.
Read now
Read now
Alain Vergnenègre & Christos Chouaïd. (2018) Review of economic analyses of treatment for non-small–cell lung cancer (NSCLC). Expert Review of Pharmacoeconomics & Outcomes Research 18:5, pages 519-528.
Read now
Read now
Kaisa Taipale, Katherine B Winfree, Mark Boye, Mickael Basson, Ghassan Sleilaty, James Eaton, Rachel Evans & Christos Chouaid. (2017) A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France. ClinicoEconomics and Outcomes Research 9, pages 505-518.
Read now
Read now
Articles from other publishers (8)
Cuc Thi Thu Nguyen, Fabio Petrelli, Stefania Scuri, Binh Thanh Nguyen & Iolanda Grappasonni. (2019) A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer. The European Journal of Health Economics 20:5, pages 763-777.
Crossref
Crossref
Yugo Chisaki, Nobuhiko Nakamura & Yoshitaka Yano. (2017) Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 40:1, pages 73-81.
Crossref
Crossref
Xucheng Yang, Pengfei Lei, Yong Huang, Zijian Zhang & Yingying Zhang. (2016) MicroRNA-133b inhibits the migration and invasion of non small cell lung cancer cells via targeting FSCN1. Oncology Letters 12:5, pages 3619-3625.
Crossref
Crossref
AIHONG JIAO, MINGHUA SUI, LIANGMING ZHANG, PING SUN, DONGMEI GENG, WEIWEI ZHANG, XIUWEN WANG & JUNXIA LI. (2016) MicroRNA-200c inhibits the metastasis of non-small cell lung cancer cells by targeting ZEB2, an epithelial-mesenchymal transition regulator. Molecular Medicine Reports 13:4, pages 3349-3355.
Crossref
Crossref
J. Cadranel, P. Créquit, T. Vieira, A.-M. Ruppert, V. Gounant, A. Lavolé & M. Wislez. (2015) Comment offrir à tous un accès aux thérapeutiques innovantes ?. Revue des Maladies Respiratoires Actualités 7:4, pages 462-475.
Crossref
Crossref
Terhi T.O. Hermanson, William J. Hrushesky, Kevin B. Knopf & Charles L. Bennett. (2015) Adding Bevacizumab to the Treatment of Patients With Non–Small-Cell Lung Cancer: Caveat Emptor. Journal of Oncology Practice 11:5, pages 363-364.
Crossref
Crossref
Xiaoshen Zhang. (2015) Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients with Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology 10:8, pages e78-e79.
Crossref
Crossref
Daniel Schneider, Giampaolo Bianchini, Denis Horgan, Stefan Michiels, Wim Witjes, Robert Hills, Juliette Plun-Favreau, Angela Brand & Mark Lawler. (2015) Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care. Public Health Genomics 18:6, pages 349-358.
Crossref
Crossref